NBC Securities Inc. Takes $40,000 Position in Elanco Animal Health Incorporated (NYSE:ELAN)

NBC Securities Inc. bought a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 3,900 shares of the company’s stock, valued at approximately $40,000.

A number of other large investors have also recently made changes to their positions in the stock. Steward Partners Investment Advisory LLC lifted its stake in Elanco Animal Health by 28.3% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 10,264 shares of the company’s stock worth $124,000 after acquiring an additional 2,264 shares during the period. DDD Partners LLC purchased a new stake in Elanco Animal Health in the fourth quarter worth about $5,974,000. Dimensional Fund Advisors LP lifted its stake in Elanco Animal Health by 6.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company’s stock worth $216,774,000 after acquiring an additional 1,074,274 shares during the period. Jones Financial Companies Lllp lifted its stake in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after acquiring an additional 2,059 shares during the period. Finally, Van ECK Associates Corp lifted its stake in Elanco Animal Health by 4.0% in the fourth quarter. Van ECK Associates Corp now owns 944,978 shares of the company’s stock worth $11,444,000 after acquiring an additional 36,239 shares during the period. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Stock Down 0.6%

ELAN stock opened at $14.19 on Friday. The company has a market cap of $7.05 billion, a price-to-earnings ratio of 35.48, a PEG ratio of 2.50 and a beta of 1.67. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.55. The firm has a 50-day moving average of $11.27 and a two-hundred day moving average of $11.44.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business’s revenue was down 1.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Morgan Stanley reduced their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Barclays reduced their target price on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Piper Sandler reduced their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a report on Wednesday, February 26th. Finally, Stifel Nicolaus boosted their target price on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, May 19th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.